Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials

We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25 feet (TA) and manual dexterity (the Box and Block Test [BBT], and 9-Hole Peg Test [9HPT]) to discriminate treatment effects in the Phase III s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Multiple sclerosis 1998-06, Vol.4 (6), p.480-486
Hauptverfasser: Goodkin, D.E., Priore, R.L., Wende, K.E., Campion, M., Bourdette, D.N., Herndon, R.M., Fischer, J.S., Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Richert, J.R., Salazar, A.M., Granger, C.V., Simon, J.H., Alam, J.J., Bartoszak, D.M., Braiman, J., Brownscheidle, C.M., Coats, M.E., Cohan, S.L., Dougherty, D.S., Kinkel, R.P., Mass, M.K., Munschauer III, F.E., Pullicino, P.M., Scherokman, B.J., Weinstock-Guttman, B., Whitham, R.H.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We compared the ability of the Kurtzke Expanded Disability Status Scale (EDSS) and a composite outcome of non-physician-based measures of time to ambulate 25 feet (TA) and manual dexterity (the Box and Block Test [BBT], and 9-Hole Peg Test [9HPT]) to discriminate treatment effects in the Phase III study of interferon beta-1a. A log-rank comparison of Kaplan-Meier curves by treatment group showed the non-physician-based composite of BBT, 9HPT, and TA was of comparable sensitivity (P = 0.013) in discriminating sustained treatment failure as the EDSS alone (P = 0.029). The composite of BBT, 9HPT, TA, and EDSS was more sensitive (P = 0.009) in discriminating sustained treatment failure than the EDSS alone. Compositive outcomes of the EDSS and non-physician-based measures of manual dexterity and timed ambulation provide an appealing strategy to reduce the number of patients required to discriminate treatment effects in MS clinical trials.
ISSN:1352-4585
1477-0970
DOI:10.1191/135245898678845179